23 Dec 2005, 12:03 GMT - The agreement in December 2003 established a collaboration to utilize molecular cytogenetics to identify and validate oncology targets. Avalon seeks to discover and develop novel therapeutics through the use of a proprietary suite of technologies based upon large-scale gene expression analysis which it calls AvalonRx.
